Enzalutamide, 160mg, 40 mg soft capsules, once daily
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration Resistant Prostate Cancer
Conditions
Metastatic Castration Resistant Prostate Cancer
Trial Timeline
Oct 1, 2015 → Aug 1, 2019
NCT ID
NCT02471469About Enzalutamide, 160mg, 40 mg soft capsules, once daily
Enzalutamide, 160mg, 40 mg soft capsules, once daily is a pre-clinical stage product being developed by Astellas Pharma for Metastatic Castration Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02471469. Target conditions include Metastatic Castration Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02471469 | Pre-clinical | Completed |
Competing Products
20 competing products in Metastatic Castration Resistant Prostate Cancer